Also a rare patient subgroup with mutations in polymerase ε (POLE) or δ1 (POLD1), associated with a hypermutated phenotype and mostly observed in microsatellite-stable (MSS)/MMR-proficient tumours [4], shows ICB responsiveness [5]. Here, POLD1 is linked to neoplasm.